|
|
|
|
Vol. 54, Issue 3, 541-546, September 1998
Department of Pharmacology, University of North Carolina at Chapel
Hill, Chapel Hill, North Carolina 27599-7365
A P2Y receptor with 65% identity to mammalian P2Y6
receptors, termed the p2y3 receptor, was recently cloned from a chick
brain cDNA library and was proposed to represent a novel P2Y receptor subtype [Mol Pharmacol 50:258-265 (1996)].
We cloned the turkey homologue of the chick p2y3 receptor, which shares
high sequence identity (97.6%) with the chick receptor, and we stably expressed this receptor and the rat P2Y6 receptor in 1321N1
human astrocytoma cells. The capacities of uridine and adenine
nucleotides to promote inositol phosphate accumulation and
intracellular Ca2+ mobilization were determined for both
receptors. UDP and 5-bromo-UDP were the most potent agonists and UTP
was a less potent full agonist at both receptors. In contrast, adenine
nucleotides and nucleotide derivatives were relatively more potent at
the turkey p2y3 receptor than at the rat P2Y6 receptor. To
determine whether the avian p2y3 receptor defined a new subtype of
mammalian P2Y receptor or was a species homologue of the mammalian
P2Y6 receptor, we screened two different human genomic
libraries and a Southern blot with a p2y3 receptor probe, under
low-stringency conditions that allowed the clear identification of the
human P2Y6 receptor gene. Our data indicated that the human
genome does not contain a receptor that is more homologous to the avian
p2y3 receptor than the P2Y6 receptor. Taken together, these
data further define the pharmacological selectivities of these
UDP-selective receptors and strongly suggest that the avian p2y3
receptor is a species homologue of the mammalian P2Y6
receptor.
This article has been cited by other articles:
![]() |
M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kadereit, P. Fustier, K. Shojaati, B. M. Frey, F. J. Frey, and M. G. Mohaupt Extracellular ATP Determines 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Activity via Purinergic Receptors J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3507 - 3516. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Herold, A.-D. Qi, T. K. Harden, and R. A. Nicholas Agonist Versus Antagonist Action of ATP at the P2Y4 Receptor Is Determined by the Second Extracellular Loop J. Biol. Chem., March 19, 2004; 279(12): 11456 - 11464. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sak, J.-M. Boeynaems, and H. Everaus Involvement of P2Y receptors in the differentiation of haematopoietic cells J. Leukoc. Biol., April 1, 2003; 73(4): 442 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-D. Qi, A. C. Zambon, P. A. Insel, and R. A. Nicholas An Arginine/Glutamine Difference at the Juxtaposition of Transmembrane Domain 6 and the Third Extracellular Loop Contributes to the Markedly Different Nucleotide Selectivities of Human and Canine P2Y11 Receptors Mol. Pharmacol., December 1, 2001; 60(6): 1375 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Fam, C. J. Gallagher, and M. W. Salter P2Y1 Purinoceptor-Mediated Ca2+ Signaling and Ca2+ Wave Propagation in Dorsal Spinal Cord Astrocytes J. Neurosci., April 15, 2000; 20(8): 2800 - 2808. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Luo, W. Zheng, M. Yan, M. G. Lee, and S. Muallem Multiple functional P2X and P2Y receptors in the luminal and basolateral membranes of pancreatic duct cells Am J Physiol Cell Physiol, August 1, 1999; 277(2): C205 - C215. [Abstract] [Full Text] [PDF] |
||||